1. Home
  2. CTSO

CTSO

Cytosorbents Corporation

Logo Cytosorbents Corporation

Health Care

Medical/Dental Instruments

Nasdaq

as 04-17-2024 12:10pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Founded: 1997 Country:
United States
United States
Employees: N/A City: PRINCETON
Market Cap: 54.8M IPO Year: N/A
Target Price: $2.50 AVG Volume (30 days): 127.8K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.64 EPS Growth: N/A
52 Week Low/High: $0.84 - $4.29 Next Earning Date: 04-30-2024
Revenue: $36,349,379 Revenue Growth: 4.79%
Revenue Growth (this year): 13.1% Revenue Growth (next year): 18.49%

Share on Social Networks: